Rosin Brian J purchased $498K of PRE

Rosin Brian J (CFO of IM8 (US) LLC) purchased 23,100 shares of Prenetics Global Ltd (PRE) at an average of $21.55 ($21.19–$22.80, $0.50M total) across 2 trades over 2026-08-24 to 2026-08-25.

Original reporting
SEC EDGAR · Rosin Brian J
Published Aug 26, 2026, 12:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 26, 2026, 12:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PRE
Neutral
high confidence
Mentioned
$PRE
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PRENeutralLow
01

Why it matters

The purchase is modest and unlikely to affect PRE's stock price.

02

Market read

Routine insider purchase with limited trading relevance.

03

What to watch

Potential upcoming product announcements not disclosed.

Relevance 5/10Novelty 4/10Timing: filing date 2026-08-26

Background

Form 4 filing discloses insider trades; used by traders to gauge insider sentiment.

Company-level read

Ticker impact

$PRENeutralHigh confidence
Context

CFO of IM8 purchased 23,100 PRE shares for $497,700 (≈$21.55 avg price) on 2026-08-24/25.

Expected impact

minimal impact; price likely unchanged.

Evidence & confidence

The transaction size is modest relative to market cap and the insider is not a direct executive of Prenetics.

Market effects

None; biotech sector unchanged.

No regional effect.

Low; isolated insider transaction.

Counterpoint

If the CFO expects near‑term upside, the buy could signal hidden value.

Key entities

  • Prenetics Global Ltd

    Biotech firm listed on Nasdaq under PRE.

  • Rosin Brian J

    CFO of IM8 (US) LLC, reporting a purchase of PRE shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PREMedAI 8/10

Prenetics Global reports Q3 results

Prenetics Global reported a Q3 net loss of $25.4M but revenue grew 171.6% year-over-year to $64.1M, exceeding estimates by $0.89M. The company's cash and current financial assets increased to $111.5M by September 30, 2026, up from $109.4M three months earlier.

$PREMed

Prenetics Global Ltd (PRE): Financial results for FY2027

Prenetics Global Ltd (PRE) furnished an SEC Form 6-K — earnings release. EX 99.1 Prenetics’ IM8 Reports Q3 2026 Revenue Growth of 266% YoY; Earliest Customers Have Returned More Than 3x Their Acquisition Cost in Under Two Years; Reaffirms FY 2026 Total Revenue Guidance of $220–230 Million and FY 2027 IM8 Revenue Guidance of $400 Million+ — Total reven

$PREMed

Prenetics Global Ltd (PRE): Financial results for Q2 2026

Prenetics Global Ltd (PRE) furnished an SEC Form 6-K — earnings release. Prenetics’ IM8 CEO and CFO Purchase $1.0 Million of Shares in the Open Market Following Second Quarter Results Cumulative Personal Investment by Leadership Since November 2025 Reaches Approximately $3.75 Million NEW YORK, N.Y. – Aug. 26, 2026 (GLOBE NEWSWIRE) – Prenetics Global L

$PREMed

Prenetics (PRE) Q2 2026 Earnings Call Transcript

Prenetics (PRE) reported Q2 2026 revenue of $46.5M, up 29% from Q1 and 3.9x from a year ago, with IM8 contributing $45M. The company raised its full-year revenue guidance to $220M-$230M and initiated 2027 guidance of $400M+. July saw record revenue of $20.9M and a 21% drop in customer acquisition cost. PRE expects Q3 to be its first positive cash flow quarter and plans to launch new products in Q4 and Q1 2027.

$PREMed

Prenetics Global Q2 Earnings Call Highlights

Prenetics (NASDAQ:PRE) reported preliminary July revenue of $21.4M, including about $20.9M from IM8, and said it reached its highest monthly level. Q2 added 118,000 new IM8 customers (140,000 active subscribers). Q2 gross profit was $30.2M (65% margin); adjusted EBITDA loss was $19M. It expects H2 2026 adjusted EBITDA loss of $8M to $12M and a first positive quarter on an adjusted free-cash-flow basis with a $1B General Catalyst facility.